Cargando…

Risk of RSV-related hospitalization is associated with gestational age in preterm (born at 29–34 wGA) infants without outpatient palivizumab administration

Palivizumab has been shown to decrease RSV-related hospitalization (RSVH) risk and reduce RSVH severity. American Academy of Pediatrics (AAP) guidance on administration of palivizumab has changed over time; in 2014, palivizumab was no longer recommended in preterm infants born at 29 weeks gestationa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Packnett, Elizabeth R., Winer, Isabelle H., Oladapo, Abiola, Wojdyla, Matthew
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2023
Materias:	Passive Immunization
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10578184/ https://www.ncbi.nlm.nih.gov/pubmed/37828711 http://dx.doi.org/10.1080/21645515.2023.2252289

Ejemplares similares

RSV-related hospitalization and outpatient palivizumab use in very preterm (born at <29 wGA) infants: 2003-2020
por: Packnett, Elizabeth R., et al.
Publicado: (2022)

Functional assays to screen and select monoclonal antibodies that target Yersinia pestis
por: Biryukov, Sergei S., et al.
Publicado: (2023)

Indications to respiratory syncytial virus immunoprophylaxis in the 29–32 wGA group: is there still room for debating?
por: Zuccotti, Gianvincenzo, et al.
Publicado: (2017)

A Systematic Review of Compliance with Palivizumab Administration for RSV Immunoprophylaxis
por: Frogel, Michael
Publicado: (2010)

Polyclonal hyper immunoglobulin: A proven treatment and prophylaxis platform for passive immunization to address existing and emerging diseases
por: Tharmalingam, Tharmala, et al.
Publicado: (2021)

Inhaled antibodies: Quality and performance considerations
por: Hickey, Anthony James, et al.
Publicado: (2021)

The biophysical principles underpinning muco-trapping functions of antibodies
por: Schaefer, Alison, et al.
Publicado: (2021)

Emerging antibody-based products for infectious diseases: Planning for metric ton manufacturing
por: Whaley, Kevin J, et al.
Publicado: (2021)

Antibody-dependent passive protection of mucosal surfaces
por: Mestecky, Jiri
Publicado: (2021)

The prospect of orally administered monoclonal secretory IgA (SIgA) antibodies to prevent enteric bacterial infections
por: Richards, Angelene, et al.
Publicado: (2021)

Revised recommendations concerning palivizumab prophylaxis for respiratory syncytial virus (RSV)
por: Bollani, Lina, et al.
Publicado: (2015)

Impact of Palivizumab on RSV Hospitalizations for Children with Hemodynamically Significant Congenital Heart Disease
por: Chang, Ruey-Kang R., et al.
Publicado: (2009)

Review of palivizumab in the prophylaxis of respiratory syncytial virus (RSV) in high-risk infants
por: Mejías, Asunción, et al.
Publicado: (2008)

Palivizumab reimbursement criteria and neonatal RSV hospitalisation: a regional retrospective review
por: Belleudi, Valeria, et al.
Publicado: (2021)

Compliance with The RSV Immunoprophylaxis Dosing Schedule in The Polish Registry for Palivizumab (2008-2014)
por: Borecka, Róża, et al.
Publicado: (2019)

WGA is a probe for migrasomes
por: Chen, Lilian, et al.
Publicado: (2019)

Siglec‐1 inhibits RSV‐induced interferon gamma production by adult T cells in contrast to newborn T cells
por: Jans, Jop, et al.
Publicado: (2018)

The impact of the recent AAP changes in palivizumab authorization on RSV-induced bronchiolitis severity and incidence
por: Capizzi, Antonino, et al.
Publicado: (2017)

Impact of the Withdrawal of Palivizumab Immunoprophylaxis on the Incidence of Respiratory Syncytial Virus (RSV) Hospitalizations Among Infants Born at 33 to 35 Weeks’ Gestational Age in the Province of Quebec, Canada: The RSV-Quebec Study
por: Papenburg, Jesse, et al.
Publicado: (2020)

Effectiveness of Palivizumab in Preventing RSV Hospitalization in High Risk Children: A Real-World Perspective
por: Homaira, Nusrat, et al.
Publicado: (2014)

Review of the Safety, Efficacy and Tolerability of Palivizumab in the Prevention of Severe Respiratory Syncytial Virus (RSV) Disease
por: O’Hagan, Shaun, et al.
Publicado: (2023)

Selective wheat germ agglutinin (WGA) uptake in the hippocampus from the locus coeruleus of dopamine-β-hydroxylase-WGA transgenic mice
por: Walling, Susan G., et al.
Publicado: (2012)

Characterization of a recombinant humanized anti-cocaine monoclonal antibody and its Fab fragment
por: Kirley, Terence L, et al.
Publicado: (2015)

Special focus issue: passive immunization
por: Zeitlin, Larry, et al.
Publicado: (2022)

Human immunoglobulin from transchromosomic bovines hyperimmunized with SARS-CoV-2 spike antigen efficiently neutralizes viral variants
por: Liu, Zhuoming, et al.
Publicado: (2021)

Plasma therapy: a passive resistance against the deadliest
por: Hansda, Anita, et al.
Publicado: (2021)

Passive immunization of the human vagina
por: Anderson, Deborah J.
Publicado: (2021)

Palivizumab: a review of its use in the protection of high risk infants against respiratory syncytial virus (RSV)
por: Geskey, Joseph M, et al.
Publicado: (2007)

Targeting of the Nasal Mucosa by Japanese Encephalitis Virus for Non-Vector-Borne Transmission
por: García-Nicolás, Obdulio, et al.
Publicado: (2018)

A comparative study of respiratory syncytial virus (RSV) prophylaxis in premature infants within the Canadian Registry of Palivizumab (CARESS)
por: Paes, B., et al.
Publicado: (2012)

Association of RSV-related hospitalization and non-compliance with Palivizumab among commercially insured infants: a retrospective claims analysis
por: Stewart, Dan L, et al.
Publicado: (2013)

2638. Respiratory Syncitial Virus Hospitalizations (RSVH) and All-Cause Bronchiolitis Hospitalizations (BH) Among 29–34 Weeks Gestational Age (wGA) Preterm Infants Before and After the 2014 American Academy of Pediatrics (AAP) Immunoprophylaxis Policy Change Using the Children’s Hospital Association’s Pediatric Health Information System (PHIS)
por: Fergie, Jaime, et al.
Publicado: (2019)

Identification of Host Factors Differentially Induced by Clinically Diverse Strains of Tick-Borne Encephalitis Virus
por: Goonawardane, Niluka, et al.
Publicado: (2022)

Unintended Consequences Following the 2014 American Academy of Pediatrics Policy Change for Palivizumab Prophylaxis among Infants Born at Less than 29 Weeks' Gestation
por: Goldstein, Mitchell, et al.
Publicado: (2021)

Asparagine-linked oligosaccharides in murine tumor cells: comparison of a WGA-resistant (WGAr) nonmetastatic mutant and a related WGA-sensitive (WGAs) metastatic line
Publicado: (1984)

Tuberculin status, socioeconomic differences and differences in all-cause mortality: experience from Norwegian cohorts born 1910–49
por: Liestøl, Knut, et al.
Publicado: (2009)

The Medicaid Cost of Palivizumab
por: Ambrose, Christopher S., et al.
Publicado: (2015)

Reformatting palivizumab and motavizumab from IgG to human IgA impairs their efficacy against RSV infection in vitro and in vivo
por: Jacobino, Shamir R., et al.
Publicado: (2018)

Risk Factors of Very Severe RSV Infections in a Multicenter Cohort of Very Preterm and Extreme Preterm Babies Receiving or Not Palivizumab
por: Mulot, Gwenaelle, et al.
Publicado: (2022)

Analysis of Minor Proteins Present in Breast Milk by Using WGA Lectin
por: Hernández-Caravaca, Iván, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_9qpmnm9uueits9mavtv72gdm8e